PT Kalbe Farma Tbk.
PTKFY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.37 | -2.11 | 3.89 | 1.41 |
| FCF Yield | 4.58% | 1.67% | 3.12% | 2.47% |
| EV / EBITDA | 15.81 | 25.11 | 17.16 | 13.99 |
| Quality | ||||
| ROIC | 12.23% | 11.52% | 14.69% | 14.60% |
| Gross Margin | 39.71% | 38.83% | 40.45% | 42.97% |
| Cash Conversion Ratio | – | 1.05 | 1.11 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | 4.09% | 5.06% | 7.77% | 5.08% |
| Free Cash Flow Growth | 104.50% | -40.38% | 58.86% | -41.06% |
| Safety | ||||
| Net Debt / EBITDA | -0.90 | -0.65 | -0.53 | -1.15 |
| Interest Coverage | 72.22 | 43.77 | 108.97 | 91.47 |
| Efficiency | ||||
| Inventory Turnover | 3.03 | 2.74 | 2.45 | 2.94 |
| Cash Conversion Cycle | 141.61 | 155.73 | 166.97 | 132.61 |